The importance of total cardiovascular risk assessment in clinical practice

European Journal of General Practice

Volumn 12, Issue 4, 2006, Pages 148-155

  Graham, Ian ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Cardiovascular risk; Clinical practice; Framingham; Guidelines; SCORE

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL PRACTICE; COHORT ANALYSIS; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; EUROPE; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; INCIDENCE; INDIVIDUALIZATION; INTERNET; ISCHEMIC HEART DISEASE; MEDLINE; MORTALITY; OBESITY; PATIENT CARE; PRACTICE GUIDELINE; PREDICTION; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; UNITED STATES; ALGORITHM; REVIEW;

ALGORITHMS; CARDIOVASCULAR DISEASES; EUROPE; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 34547475458     PISSN: 13814788     EISSN: None     Source Type: Journal    
DOI: 10.1080/13814780600976282     Document Type: Article

References (50)

1. De Backer, G., Ambrosioni, E., Borch-Johnsen, K., Brotons, C., Cifkova, R. and Dallongeville, J. (2003) European guidelines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil, 10, p. S1.
2. Dawber, TR, Kannel, WB, Revotskie, N. and Kagan, A. (1962) The epidemiology of coronary heart disease-the Framingham enquiry. Proc R Soc Med, 55, pp. 265-271.
3. Greenland, P., Knoll, MD, Stamler, J., Neaton, JD, Dyer, AR and Garside, DB (2003) Major risk factors as antecedents of fatal and nonfatal coronary heart disease. JAMA, 290, pp. 891-897.
4. Khot, UN, Khot, MB, Bayzer, CT, Sapp, SK, Ohman, EM and Brener, SJ (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 290, pp. 898-904.
5. Conroy, RM, Pyorala, K., Fitzgerald, AP, Sans, S., Menotti, A. and De Backer, G. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J, 24, pp. 987-1003.
6. Kannel, WB and Wilson, PW. (1995) An update on coronary risk factors. Med Clin North Am, 79, pp. 951-971.
7. Cucherat, M., Bonnefoy, E. and Tremeau, G. (2004) Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction (Cochrane Review). The Cochrane Library 2004; Issue I, John Wiley & Sons Ltd, Chichester, UK
8. Keeley, EC, Boura, JA and Grines, CL. (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet, 361, pp. 13-20.
9. Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-specified relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, pp. 1903-1913.
10. Downs, JR, Clearfield, M., Weis, S., Whitney, E., Shapiro, DR and Beere, PA (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279, pp. 1615-1622.
11. Shepherd, J., Cobbe, SM, Ford, I., Isles, CG, Lorimer, AR and MacFarlane, PW (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 333, pp. 1301-1307.
12. Lindstrom, J., Eriksson, JG, Valle, TT, Aunola, S., Cepaitis, Z. and Hakumaki, M. (2003) Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes mellitus prevention study: Results from a randomized clinical trial. J Am Soc Nephrol, 14, p. S108.
13. The Diabetes Prevention Program (DPP) Research Group (2002) The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care, 25, pp. 2165-2171.
14. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, pp. 1383-1389.
15. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 339, pp. 1349-1357.
16. Pfeffer, MA, Sacks, FM, Moye, LA, Brown, L., Rouleau, JL and Hartley, LH (1995) Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol, 76, pp. 98C-106C.
17. Mulcahy, R., Hickey, N., Graham, I. and McKenzie, G. (1975) Factors influencing long-term prognosis in male patients surviving a first coronary attack. Br Heart J, 37, pp. 158-165.
18. Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, NH and Eberlein, KA (1990) Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet, 335, pp. 827-838.
19. Kannel, WB, McGee, DL, Helbert, P., Fiebach, NH and Ebeilrleinte, A. (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care, 2, pp. 120-126.
20. De Backer, G., Ambrosioni, E., Borch-Johnsen, K., Brotons, C., Cifkova, R. and Dallongeville, J. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 24, pp. 1601-1610.
21. Wilson, PW, D'Agostino, RB, Levy, D., Belanger, AM, Silbershatz, H. and Kannel, WB. (1998) Prediction of coronary heart disease using risk factor categories. Circulation, 97, pp. 1837-1847.
22. (1998) Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart, 80, pp. 1-29.
23. (1995) Guidelines for the management of mildly raised blood pressure in New Zealand.
24. World Health Organization (2003) The world health report 2003-shaping the future, World Health Organization, Geneva
25. (2001) Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet, 357, pp. 995-1001.
26. (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J, 22, pp. 554-572.
27. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, pp. 7-22.
28. Sever, PS, Dahlof, B., Poulter, NR, Wedel, H., Beevers, G. and Caulfield, M. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet, 361, pp. 1149-1158.
29. The Framingham Heart Study.
30. Information for researchers. The Framingham Heart Study.
31. (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285, pp. 2486-2497.
32. Wilson, PWF, D'Agostino, RB, Levy, D., Belanger, AM, Silbershatz, H. and Kannel, WB. (1998) Prediction of coronary heart disease using risk factor categories. Circulation, 97, pp. 1837-1847.
33. Haq, IU, Ramsay, LE, Yeo, WW, Jackson, PR and Wallis, EJ. (1999) Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart, 81, pp. 40-46.
34. D'Agostino, RB Sr, Grundy, S., Sullivan, LM and Wilson, P. (2001) Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA, 286, pp. 180-187.
35. Fried, LP, Borhani, NO, Enright, P., Furberg, CD, Gardin, JM and Kronmal, RA (1991) The Cardiovascular Health Study: Design and rationale. Ann Epidemiol, 1, pp. 263-276.
36. Garcia-Palmieri, MR, Costas Jr, R., Cruz-Vidal, M., Cortes-Alicea, M., Patterne, D. and Rojas-Franco, L. (1978) Urban-rural differences in coronary heart disease in a low incidence area. The Puerto Rico heart study. Am J Epidemiol, 107, pp. 206-215.
37. Stern, MP. (1984) Honolulu Heart Study: Review of epidemiologic data and design. Prog Clin Biol Res, 147, pp. 93-104.
38. Lee, ET, Welty, TK, Fabsitz, R., Cowan, LD, Le, NA and Oopik, AJ (1990) The Strong Heart Study. A study of cardiovascular disease in American Indians: Design and methods. Am J Epidemiol, 132, pp. 1141-1155.
39. (1989) The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol, 129, pp. 687-702.
40. Menotti, A., Puddu, PE and Lanti, M. (2000) Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J, 21, pp. 365-370.
41. Thomsen, TF, McGee, D., Davidsen, M. and Jorgensen, T. (2002) A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol, 31, pp. 817-822.
42. Hense, HW, Schulte, H., Lowel, H., Assmann, G. and Keil, U. (2003) Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J, 24, pp. 937-945.
43. Folsom, AR, Aleksic, N., Park, E., Salomaa, V., Juneja, H. and Wu, KK. (2001) Prospective study of fibrinolytic factors and incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol, 21, pp. 611-617.
44. (2002) Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA, 288, pp. 2015-2022.
45. Graham, IM, Daly, LE, Refsum, HM, Robinson, K., Brattstrom, LE and Ueland, PM (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA, 277, pp. 1775-1781.
46. Levenson, J., Giral, P., Razavian, M., Gariepy, J. and Simon, A. (1995) Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol, 15, pp. 1263-1268.
47. Ernst, E. and Resch, KL. (1995) Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J, 16, pp. 47-52.
48. Hwang, SJ, Ballantyne, CM, Sharrett, AR, Smith, LC, Davis, CE and Gotto Jr, AM (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation, 96, pp. 4219-4225.
49. Ridker, PM, Hennekens, CH, Roitman-Johnson, B., Stampfer, MJ and Allen, J. (1998) Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet, 351, pp. 88-92.
50. Ridker, PM, Rifai, N., Clearfield, M., Downs, JR, Weis, SE and Miles, JS (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med, 344, pp. 1959-1965.